MAPT and Alzheimer disease: Longitudinal tau-PET cohorts in patients with high-risk preclinical AD provided special distribution of deposition of tau that can allow to staging in-vivo neurodegeneration according to tau levels in preclinical AD (Johnson et al., 2016).